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Abstract
Background: Noni (Morinda citrifolia) juice has demonstrated antioxidant activity in vitro and in vivo.
To evaluate this activity in humans, noni juice from Tahiti (TNJ) was evaluated in a 30 day, double-
blind, and placebo controlled clinical trial with 285 current heavy smokers. Research participants
were randomly assigned to three daily treatment groups: 118 mL placebo, 29.5 mL TNJ, and 118
mL TNJ. Plasma superoxide anion radicals (SAR) and lipid hydroperoxide (LOOH) levels were
measured pre and post-intervention.
Results: After 30 days, mean SAR decreased from 0.26 ± 0.14 to 0.19 ± 0.10 μmol/mL in the 29.5
mL dose group (P < 0.01) and from 0.26 ± 0.22 to 0.18 ± 0.11 μmol/mL in the 118 mL dose group
(P < 0.001). LOOH levels decreased from 0.53 ± 0.19 to 0.40 ± 0.10 μmol/mL in the 29.5 mL dose
group (P < 0.001) and from 0.55 ± 0.21 to 0.40 ± 0.14 μmol/mL in the 118 mL dose group (P <
0.001). No significant reductions in SAR or LOOH levels were observed in the placebo group.
Conclusion: The results suggest an antioxidant activity from noni juice in humans exposed to
tobacco smoke, thereby replicating the results found previous chemical and in vivo tests.
Background
Exposure to cigarette smoke results in the generation of
oxygen free radicals that account, in part, for the patho-
genesis of smoking related diseases [1-3]. It is estimated
that about 1017 oxidant molecules are present in each puff
of cigarette smoke [4]. Smoking results in a subsequent
state of oxidative stress, due to the formation of circulat-
ing lipid peroxidation products in the blood [5-7], such as
lipid hydroperoxides (LOOH), as well as superoxide
anion radicals (SAR). Increases in LOOH and SAR have
been measured in the blood following exposure to ciga-
rette smoke [8-10]. The induction of lipid peroxidation is
largely due to free-radical reactions involving polyunsatu-
rated fatty acids in biological membranes. The unsatu-
rated bonds undergo autocatalytic or enzymatic
processing to form harmful LOOH [11]. The active LOOH
quickly decompose to aldehydes and alkenals. All of these
are active in DNA binding and are responsible for major
endogenous cell damage.
Previous research has established that fruits and vegeta-
bles are major sources of dietary antioxidants [12]. Epide-
miological studies have demonstrated that consumption
of fruits and vegetables may reduce free-radical-induced
Published: 6 October 2009
Chemistry Central Journal 2009, 3:13 doi:10.1186/1752-153X-3-13
Received: 1 July 2009
Accepted: 6 October 2009
This article is available from: http://journal.chemistrycentral.com/content/3/1/13
© 2009 Wang et al Chemistry Central Journal 2009, 3:13 http://journal.chemistrycentral.com/content/3/1/13
Page 2 of 5
(page number not for citation purposes)
oxidative damage and lipid peroxidation in cigarette
smokers [13]. Morinda citrifolia (noni) is an evergreen or
small tree that grows in many tropical regions of the
world. The fruit of this tree has a history of use as both
food and medicine among Pacific Islanders and in South-
east Asia [14,15]. Several reports have described various
potential health benefits of noni fruit [16,18], including
immunomodulation [19,20] and antioxidant activities in
vitro and in vivo [21-23]. The European Union-approved
form of noni fruit juice from Tahiti (TNJ), has been found
to exert an antioxidant effect in human athletes, thereby
increasing exercise endurance [24]. This is also the mech-
anism by which TNJ provided protection against carbon-
tetrachloride-induced liver damage in Sprague-Dawley
rats [25]. Hence, TNJ may also mitigate oxidative damage
and consequent lipid peroxidation in cigarette smokers.
To further evaluate this potential effect, a 30-day, placebo-
controlled, double-blinded, and randomized clinical trial
was conducted with research participants who were cur-
rent heavy smokers.
Results and discussion
There were no significant differences in demographics
between the groups. There were no differences in a 1:1
gender ratio, with the ethnic compositions of the groups
being primarily Caucasian, 80 - 89%, and African Ameri-
can, 9.4 - 18%. The mean age in each group ranged from
37 to 43 yr. There was no difference in the mean number
of cigarettes smoked each day (26 - 29). During the course
of the trial, no adverse health events due to TNJ or placebo
ingestion were observed in any of the participants.
Mean pre and post-test SAR and LOOH values are com-
pared in Table 1. No significant inter-group differences
were observed in pre-test values. There was no significant
change in SAR or LOOH levels in the placebo group. There
was a trend for lower post-test SAR levels in both TNJ
groups than in the placebo group, although this difference
was not statistically significant. However, mean post-test
SAR levels in both TNJ groups were significantly lower
than their pre-test values. Percent reductions in SAR in the
29.5 and 118 mL TNJ groups were 26.9% (P < 0.001) and
30.8% (P  < 0.001), respectively. The mean post-test
plasma LOOH levels in both TNJ groups were 32% lower
than that of the placebo group (P < 0.001). Mean LOOH
was reduced in the 29.5 mL TNJ group by 24.5% (P <
0.001), while a 27.3% reduction was observed in the 118
mL TNJ group (P < 0.001).
Gender-specific mean SAR and LOOH levels in the TNJ
groups are compared in Table 2. Significant intra-group
reductions in SAR and LOOH occurred in both the males
and females of the TNJ groups. The degrees of LOOH
reduction in males and females are essentially the same as
observed in the combined gender analysis. A comparison
of post-test values revealed no significant differences
between males and females, as well as between TNJ dose
groups. This latter observation suggests a threshold of
antioxidant activity is reached by a daily dose of 29.5 mL.
It is important to note that the placebo contains grape and
blueberry juices, the fruits of which have been shown to
exhibit antioxidant activities in humans [26]. As such, the
placebo also serves as a point of comparison between TNJ
and other common fruit juices. The lack of a statistically
significant difference in post-test SAR levels between the
TNJ groups and the placebo may be explained by the fact
that phytochemicals in grapes have the ability to scavenge
SAR [27,28]. Although the SAR scavenging ability of the
grape juice was not great enough to result in significant
reductions in heavy smokers, there was enough activity to
lower post-test levels in the placebo group to a point
where the confidence interval of the mean overlapped
those of the TNJ groups. The post-test means of the TNJ
groups were, however, significantly less than their pre-test
means, as well as the placebo pre-test mean. Therefore, the
ability of TNJ to lower SAR in heavy smokers is demon-
strated in this trial and is somewhat greater than the grape
and blueberry juice blend of the placebo, although only
marginally so.
The most significant effect of TNJ in this trial was on mean
post-test plasma LOOH concentrations. In both TNJ
groups, these were significantly less than pre-test values
and the post-test mean of the placebo group. The differen-
tial effect on LOOH and SAR sheds some light on the
potential target of the antioxidant action of noni juice.
SAR is converted to H2O2 by superoxide dismutase, from
which the hydroxyl radical is formed by Fenton-type
reduction. The hydroxyl radical triggers chain peroxida-
tion of unsaturated lipids to form LOOH [29]. As smok-
ing generated plasma LOOH levels appear to be more
significantly reduced than SAR, it is likely that the
hydroxyl radical is a major target of the antioxidant activ-
ity of noni juice. Further research is required to elucidate
the mechanisms responsible for the preferential lowering
of LOOH over SAR.
Table 1: Serum free-radical levels in current heavy smokers.
Placebo 29.5 mL TNJ 118 mL TNJ
Serum SAR (μmol/mL)
Pre-test 0.23 ± 0.15 0.26 ± 0.14 0.26 ± 0.22
Post-test 0.21 ± 0.17 0.19 ± 0.10* 0.18 ± 0.11**
Serum LOOH (μmol/mL)
Pre-test 0.58 ± 0.22 0.53 ± 0.19 0.55 ± 0.21
Post-test 0.59 ± 0.21 0.40 ± 0.10*** 0.40 ± 0.14***
* P < 0.01, ** P < 0.001 compared to pre-test values
*** P < 0.001 compared to pre-test values and placeboChemistry Central Journal 2009, 3:13 http://journal.chemistrycentral.com/content/3/1/13
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Experimental
The research protocol of this trial was approved by the
Institutional Review Board Committee of the University
of Illinois College of Medicine at Rockford, following an
ethics review. The trial was conducted in accord with the
Declaration of Helsinki and written informed consent was
obtained from all participants.
Adult heavy smokers were recruited for enrollment in this
study. The inclusion criteria were 18 to 65 years in age,
smoker of more than 20 cigarettes per day, a smoking his-
tory exceeding one year, and no concurrent use, or use in
the previous three months, of prescription medication or
antioxidant vitamins. For ethics reasons, fruits and vegeta-
bles were not restricted from the diets of the subjects. Both
males and females were enrolled in equal proportions.
For this trial noni juice from Tahiti (TNJ) was used (Tahi-
tian Noni International Inc., Provo, Utah, USA). The pla-
cebo consisted of a blend of grape and blueberry juices
and natural cheese flavor to mimic the flavor of TNJ.
Study volunteers were randomly assigned to one of three
daily treatment groups: 118 mL placebo (n = 42), 29.5 mL
TNJ daily (n = 121), and 118 mL TNJ (n = 122). Partici-
pants and investigators were blinded as to which treat-
ment group each volunteer was assigned to. The male to
female ratio of each group was 1:1. Those in the 29.5 mL
TNJ group were asked to drink the juice all at once in the
morning and on an empty stomach. Those in the other
two groups were asked to drink 59 mL twice daily, once in
the morning on an empty stomach and once before bed-
time. Additionally, volunteers were asked to drink one
cup of water after consuming TNJ. The volunteers were
asked to follow this schedule for 30 days.
Upon enrollment, 10 mL of whole blood was drawn from
each volunteer and collected in tubes containing heparin,
then centrifuged at 1,500 × g to obtain plasma for the
baseline determination of SAR and LOOH levels. Baseline
plasma SAR and LOOH levels represented the initial oxi-
dative status in current smokers. At the conclusion of the
30-day trial, a 10 mL blood sample was again drawn from
each study participant, and plasma SAR and LOOH levels
were again determined to assess the impact of TNJ on the
oxidative status of current smokers.
The plasma SAR level of subjects was determined by a
Tetrazolium Nitro Blue (TNB) assay, as described previ-
ously [30]. In this assay, SAR reduces TNB into formazan
blue, which absorbs light at 602 nm. An SAR scavenger
reduces the absorbance by reacting with SAR, thus pre-
venting formazan blue formation. Also in this assay,
NADH generates SAR under aerobic conditions, with
phenazine methosulfate (PMS) as the catalyst.
The plasma LOOH concentrations were determined by
the leucomethylene blue (LMB) assay, as described previ-
ously [31,32]. Plasma samples were incubated for 5 min-
utes at room temperature with LMB reagent solution; 1.6
mmol LMB, 0.0055% hemoglobin (w/v), 1.4% (v/v) tri-
ton X-100, and 8% (v/v) dimethylformide in 0.05 M
potassium phosphate buffer (pH 5). In the presence of
hemoglobin, LOOH oxidizes leucomethylene blue to
methylene blue, which absorbs at 660 nm. Plasma LOOH
concentration was calculated from the absorbance at this
wavelength, against a cumene hydroperoxide generated
standard curve.
A power analysis was performed to estimate the number
of cases needed to detect a significant effect [33]. The
study was designed to compare pre- and post-test data. All
analyses were conducted on unpaired cases of each group
and included intent-to-treat analysis. The study comple-
tion rate among all groups was greater than 73%, with no
significant differences between any of the groups (Pearson
chi-square test P > 0.5). All data were expressed as a mean,
± standard deviation (SD). To assess the effect of TNJ on
plasma SAR and LOOH levels, the averaged means of each
group were compared before and after the trial using Stu-
dent's T-test. Analysis of variance (ANOVA) was used to
compare intergroup differences in plasma SAR and LOOH
levels.
Conclusion
SAR and LOOH levels are biomarkers for degenerative dis-
eases associated with cigarette smoking [34-36]. As noted
Table 2: Serum free-radicals by gender and TNJ dose.
SAR (μmol/mL) LOOH (μmol/mL)
29.5 mL TNJ 118 mL TNJ 29.5 mL TNJ 118 mL TNJ
Female
Pre-test 0.26 ± 0.14 0.26 ± 0.24 0.52 ± 0.23 0.53 ± 0.16
Post-test 0.19 ± 0.10 ** 0.18 ± 0.12 * 0.39 ± 0.11 *** 0.39 ± 0.14 ***
Male
Pre-test 0.25 ± 0.14 0.26 ± 0.21 0.53 ± 0.16 0.57 ± 0.25
Post-test 0.19 ± 0.10 ** 0.19 ± 0.12 * 0.40 ± 0.10 *** 0.40 ± 0.11 ***
* P < 0.05, ** P < 0.01, *** P < 0.001Chemistry Central Journal 2009, 3:13 http://journal.chemistrycentral.com/content/3/1/13
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earlier, molecular epidemiologic studies have demon-
strated that SAR and LOOH levels in smokers are signifi-
cantly higher than in nonsmokers [37]. The results of this
trial substantiate the antioxidant properties of noni juice
observed in vitro and in vivo, as well as demonstrate an
effect under conditions of oxidative stress produced by
heavy smoking.
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